Search | Clinical Trials Finder

Conditions: Hematologic Malignancies, Solid Tumors
Interventions: Not listed
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Atrial Fibrillation, Stroke
Interventions: dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more

Conditions: Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival
Interventions: Disease assessments, Tumor Biopsy, Blood test; Diagnostic Test · Procedure
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leber Hereditary Optic Neuropathy
Interventions: GS010, Sham Intravitreal Injection; Genetic · Other
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Pasadena, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Cancer, Pregnancy
Interventions: Not listed
Lead sponsor: University Hospital, Gasthuisberg; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2032
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Interventions: No interventional drug product utilized in this follow-up study; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 19 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2038
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 1 more

Conditions: Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)
Interventions: KYV-101; Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2041
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Leukocyte Adhesion Deficiency
Interventions: Not listed
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Cord Injuries
Interventions: Magnetic Resonance Imaging (MRI); Diagnostic Test
Lead sponsor: Lineage Cell Therapeutics, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 3 more

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Transverse Myelitis
Interventions: Q-Cells®; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Interventions: Blood tests; Genetic
Lead sponsor: Calimmune, Inc.; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Long Term Follow-up
Interventions: Non-interventional; Other
Lead sponsor: Arbutus Biopharma Corporation; Industry
Eligibility: 20 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: San Diego, California • Miami, Florida • Hillsborough, New Jersey

Conditions: HIV
Interventions: Gene modified therapy; Biological
Lead sponsor: American Gene Technologies International Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2038
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: Prademagene Zamikeracel; Combination Product
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2045
U.S. locations: 4
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more

Conditions: Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions: SCC DBS; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Prostate Cancer
Interventions: Follow-up; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 55 Years to 120 Years · Male only
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 52
States / cities: Fort Lauderdale, Florida • Jupiter, Florida • Miami Beach, Florida + 39 more

Conditions: CKD, ESRD
Interventions: Long term hemodialysis catheter; Device
Lead sponsor: Medical Components, Inc dba MedComp; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more

Conditions: Overactive Bladder
Interventions: Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U; Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Middlebury, Connecticut

Conditions: Infections, Papillomavirus, Papillomavirus Vaccines
Interventions: CervarixTM, HPV investigational vaccine GSK568893A, different formulations; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 383 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Denver, Colorado • Golden, Colorado • Salt Lake City, Utah

Conditions: Temporomandibular Joint and Muscle Disorder
Interventions: Biobehavioral, Active Coping/Attention Intervention; Behavioral
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 95 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • West Los Angeles, California + 4 more

Conditions: Genital Herpes Simplex Type 2
Interventions: Observational; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more

Search by objective public record fields.

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Long-term Follow-up of Subjects Treated With CAR T Cells

RESCUE and REVERSE Long-term Follow-up

Effects of Oncological Treatment During Pregnancy on Mother and Child

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1

LTFU for Gene Transfer Subjects With Hemophilia B

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression

S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)

Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity